Contract Year 2015 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs (79 FR 29844) (hereinafter referred to as the Parts C and D Overpayment Final Rule), which provided, among other things, that an MAO or PDP sponsor has identified an overpayment when the MAO or PDP sponsor has determined, or should have determined through the exercise of reasonable diligence, that the MAO or PDP sponsor has received an overpayment
To win FDA authorization, companies generally must show that their products will reduce disease among adult tobacco users without attracting underage use by teens and adolescents
Under our analysis, our proposed scoring methodology would not negatively impact MIPS eligible clinicians whose average costs for a specific cost measure are around the median
CMS notes that, if CMS were to finalize this alternative approach, CMS would be unable to use this approach to calculate the benchmark period manufacturer price in the case of a new NDC-9 of an existing Part D rebatable drug with base date AMP that does not overlap with the time period described in proposed 428.202(c)(1) or (2)
